RDY vs SUN vs PRGO vs AMRX vs TEVA

For growth investors, Dr.

Reddy's Laboratories Limited (RDY) is the stronger pick with 16. 6% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Sunoco LP (SUN) offers the better valuation at 18. 5x trailing P/E (9. 4x forward), making it the more compelling value choice. Analysts rate Dr. Reddy's Laboratories Limited (RDY) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Sunoco LP (SUN) is the cheapest at 18.

5x versus Amneal Pharmaceuticals, Inc. at 62. 4x. On forward P/E, Dr. Reddy's Laboratories Limited is actually cheaper at 0. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Teva Pharmaceutical Industries Limited (TEVA) delivered a total return of +246.

2%, compared to -60. 1% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: SUN returned +209. 2% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sunoco LP (SUN) is the lower-risk stock at 0.

13β versus Perrigo Company plc's 1. 18β — meaning PRGO is approximately 834% more volatile than SUN relative to the S&P 500. On balance sheet safety, Amneal Pharmaceuticals, Inc. (AMRX) carries a lower debt/equity ratio of 13% versus 2% for Teva Pharmaceutical Industries Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Dr.

Reddy's Laboratories Limited (RDY) is pulling ahead at 16. 6% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Teva Pharmaceutical Industries Limited grew EPS 182. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, RDY leads at 14. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Dr.

Reddy's Laboratories Limited (RDY) is the more profitable company, earning 17. 4% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 17. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RDY leads at 22. 1% versus -0. 2% for AMRX. At the gross margin level — before operating expenses — RDY leads at 58. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Dr.

Reddy's Laboratories Limited (RDY) trades at 0. 2x forward P/E versus 14. 5x for Teva Pharmaceutical Industries Limited — 14. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.

In this comparison, PRGO (9.

8% yield), SUN (7. 1% yield), RDY (0. 6% yield) pay a dividend. AMRX, TEVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Sunoco LP (SUN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

13), 7. 1% yield, +209. 2% 10Y return). Both have compounded well over 10 years (SUN: +209. 2%, AMRX: -54. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RDY (Healthcare) and SUN (Energy) and PRGO (Healthcare) and AMRX (Healthcare) and TEVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RDY is a mid-cap high-growth stock; SUN is a small-cap income-oriented stock; PRGO is a small-cap income-oriented stock; AMRX is a small-cap quality compounder stock; TEVA is a mid-cap quality compounder stock. RDY, SUN, PRGO pay a dividend while AMRX, TEVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.